Western Australia’s Little Inexperienced Pharma (ASX:LGP) and Curtin College have teamed as much as examine the potential of medicinal hashish therapy choices for weight problems and associated well being points.
Marijuana is well-known for inflicting the “munchies“, which is considered brought on by the cannabinoid tetrahydrocannabinol (THC) – the identical compound that creates marijuana’s excessive. However hashish is far more than THC as you’ll see on HG’s big list of cannabinoids.
New analysis at Curtin’s Medical Faculty will try and establish mixtures of cannabinoids which will produce results of a sense of fullness; reducing urge for food.
“Among the greater than 100 cannabinoids current within the hashish plant have been proven to have therapeutic potential for weight problems,” said Curtin’s Professor Marco Falasca, who might be main the examine. “Our analysis will search to unlock additional understanding of the function these cannabinoids can play in regulating intestine perform, their mechanism of motion and optimum dosing for therapeutic impact to assist weight reduction.”
Little Inexperienced Pharma is to fund the analysis, which can happen in three levels – with the ultimate stage anticipated to be accomplished by February subsequent 12 months.
“Supporting any such analysis, which research the usage of medicinal hashish in tough to deal with situations, is a cornerstone of our enterprise and key to our R&D technique,” mentioned LGP Head of Analysis and Innovation Dr Leon Warne.
In different current information from LGP, the corporate introduced final month it had signed a three-year distribution agreement with AMP for the distribution of LGP-branded hashish oil medicines in Germany, and a four-year agreement with PharmaServe for the distribution of its oil-based medicines and hashish flower in Greece.
Little Inexperienced Pharma is a vertically built-in medical hashish firm, with operations from cultivation and manufacturing via to manufacturing and distribution. It has a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility able to producing extra 20 tonnes of medicinal hashish biomass yearly in Europe (Denmark); acquired last year. Nearer to house, LGP’s indoor cultivation and manufacturing facility situated in Western Australia is able to producing ~3 tonnes of medicinal hashish biomass each year.